Iterum Therapeutics Plc Stock Market Value
| ITRM Stock | USD 0.21 0.01 2.55% |
| Symbol | Iterum |
Will Pharmaceuticals sector continue expanding? Could Iterum diversify its offerings? Factors like these will boost the valuation of Iterum Therapeutics. Market participants price Iterum higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Iterum Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.67) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Understanding Iterum Therapeutics PLC requires distinguishing between market price and book value, where the latter reflects Iterum's accounting equity. The concept of intrinsic value - what Iterum Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Iterum Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Iterum Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Iterum Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Iterum Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Iterum Therapeutics.
| 11/22/2025 |
| 02/20/2026 |
If you would invest 0.00 in Iterum Therapeutics on November 22, 2025 and sell it all today you would earn a total of 0.00 from holding Iterum Therapeutics PLC or generate 0.0% return on investment in Iterum Therapeutics over 90 days. Iterum Therapeutics is related to or competes with Intensity Therapeutics, IBio Common, Rallybio Corp, Pluri, AN2 Therapeutics, Boundless Bio, and TAO Synergies. Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infecti... More
Iterum Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Iterum Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Iterum Therapeutics PLC upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.19) | |||
| Maximum Drawdown | 26.92 | |||
| Value At Risk | (8.89) | |||
| Potential Upside | 9.38 |
Iterum Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Iterum Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Iterum Therapeutics' standard deviation. In reality, there are many statistical measures that can use Iterum Therapeutics historical prices to predict the future Iterum Therapeutics' volatility.| Risk Adjusted Performance | (0.13) | |||
| Jensen Alpha | (1.34) | |||
| Total Risk Alpha | (1.66) | |||
| Treynor Ratio | (0.46) |
Iterum Therapeutics February 20, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | (0.45) | |||
| Mean Deviation | 4.85 | |||
| Coefficient Of Variation | (542.11) | |||
| Standard Deviation | 6.47 | |||
| Variance | 41.88 | |||
| Information Ratio | (0.19) | |||
| Jensen Alpha | (1.34) | |||
| Total Risk Alpha | (1.66) | |||
| Treynor Ratio | (0.46) | |||
| Maximum Drawdown | 26.92 | |||
| Value At Risk | (8.89) | |||
| Potential Upside | 9.38 | |||
| Skewness | (0.13) | |||
| Kurtosis | 1.89 |
Iterum Therapeutics PLC Backtested Returns
Iterum Therapeutics PLC holds Efficiency (Sharpe) Ratio of -0.18, which attests that the entity had a -0.18 % return per unit of risk over the last 3 months. Iterum Therapeutics PLC exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Iterum Therapeutics' Standard Deviation of 6.47, market risk adjusted performance of (0.45), and Risk Adjusted Performance of (0.13) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 2.59, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Iterum Therapeutics will likely underperform. At this point, Iterum Therapeutics PLC has a negative expected return of -0.97%. Please make sure to check out Iterum Therapeutics' treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if Iterum Therapeutics PLC performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.76 |
Good predictability
Iterum Therapeutics PLC has good predictability. Overlapping area represents the amount of predictability between Iterum Therapeutics time series from 22nd of November 2025 to 6th of January 2026 and 6th of January 2026 to 20th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Iterum Therapeutics PLC price movement. The serial correlation of 0.76 indicates that around 76.0% of current Iterum Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.76 | |
| Spearman Rank Test | 0.69 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Iterum Therapeutics Correlation, Iterum Therapeutics Volatility and Iterum Therapeutics Performance module to complement your research on Iterum Therapeutics. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Iterum Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.